Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. A lot of organizations like to say publicly that “the client comes first.” ...

Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

Amgen's longer-acting version of the drug – Neulasta (pegfilgrastim) – grew 5 per cent to approach $4.4 billion last year. That product could also be under threat, however, as it is due to ...

Last month, Sandoz revealed that the FDA had rejected its biosimilar of Amgen's Neulasta (pegfilgrastim), a longer lasting version of Neupogen. The FDA is set to make a decision over the coming ...